atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout
Portfolio Pulse from
atai Life Sciences' stock is positively impacted by new data from GH Research's Phase 2 trial, which supports atai's own treatment-resistant depression trials. Jefferies maintains a 'Buy' rating with a $5 price target.
February 03, 2025 | 6:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
atai Life Sciences benefits from positive data from GH Research's trial, which supports its own treatment-resistant depression trials. Jefferies maintains a 'Buy' rating with a $5 price target.
The positive data from GH Research's trial reduces the risk associated with atai's own trials, leading to a positive outlook from analysts. Jefferies' reiteration of a 'Buy' rating and a $5 price target further supports a positive short-term impact on atai's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90